Objective:
The drug ezogabine was tested in a randomized clinical trial of ALS participants to determine whether it could decrease motor neuron hyperactivity, which leads to nerve damage. Randomized participants received 600 mg/d or 900 mg/d over a 10-week period.
Conclusions:
Ezogabine decreased motor neuron hyperactivity in ALS participants, suggesting this metric could be used as biomarker in future trials.